JP2024543479A - 多環式化合物 - Google Patents

多環式化合物 Download PDF

Info

Publication number
JP2024543479A
JP2024543479A JP2024528455A JP2024528455A JP2024543479A JP 2024543479 A JP2024543479 A JP 2024543479A JP 2024528455 A JP2024528455 A JP 2024528455A JP 2024528455 A JP2024528455 A JP 2024528455A JP 2024543479 A JP2024543479 A JP 2024543479A
Authority
JP
Japan
Prior art keywords
pharma
compound
acceptable salt
ceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543479A5 (https=
Inventor
ソロモン、アトリー
Original Assignee
アトリー バイオテック、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトリー バイオテック、インク． filed Critical アトリー バイオテック、インク．
Publication of JP2024543479A publication Critical patent/JP2024543479A/ja
Publication of JP2024543479A5 publication Critical patent/JP2024543479A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024528455A 2021-11-13 2022-11-11 多環式化合物 Pending JP2024543479A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202163279094P 2021-11-13 2021-11-13
US63/279,094 2021-11-13
US202163282264P 2021-11-23 2021-11-23
US63/282,264 2021-11-23
US202263299749P 2022-01-14 2022-01-14
US63/299,749 2022-01-14
US202263317980P 2022-03-09 2022-03-09
US63/317,980 2022-03-09
US202263321915P 2022-03-21 2022-03-21
US63/321,915 2022-03-21
US202263336476P 2022-04-29 2022-04-29
US63/336,476 2022-04-29
US202263375050P 2022-09-08 2022-09-08
US63/375,050 2022-09-08
PCT/US2022/049719 WO2023086580A2 (en) 2021-11-13 2022-11-11 Multicyclic compounds

Publications (2)

Publication Number Publication Date
JP2024543479A true JP2024543479A (ja) 2024-11-21
JP2024543479A5 JP2024543479A5 (https=) 2025-11-18

Family

ID=86336491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528455A Pending JP2024543479A (ja) 2021-11-13 2022-11-11 多環式化合物

Country Status (6)

Country Link
US (1) US20250100987A1 (https=)
EP (1) EP4429656A4 (https=)
JP (1) JP2024543479A (https=)
CA (1) CA3238026A1 (https=)
IL (1) IL312774A (https=)
WO (1) WO2023086580A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024226703A2 (en) * 2023-04-27 2024-10-31 The Scripps Research Institute Asymmetric synthesis and diversification of a stabilized salvinorin a scaffold
CN118267384B (zh) * 2024-03-27 2024-12-20 徐州医科大学 κ阿片受体激动剂在制备预防和/或治疗颞叶癫痫药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088466A1 (en) * 2005-06-17 2009-04-02 University Of Iowa Research Foundation Opioid receptor ligands
US11512075B2 (en) * 2017-06-14 2022-11-29 The Scripps Research Institute Synthesis of 20-nor-salvinorin A
US20210186927A1 (en) * 2018-04-13 2021-06-24 Blumentech, S.L. Combination product for the induction and/or maintenance of general anesthesia
US10556889B1 (en) * 2018-12-19 2020-02-11 Blue Sky Pharmaceuticals, LLC Salvinorin derivatives

Also Published As

Publication number Publication date
WO2023086580A3 (en) 2023-07-06
IL312774A (en) 2024-07-01
WO2023086580A2 (en) 2023-05-19
EP4429656A2 (en) 2024-09-18
CA3238026A1 (en) 2023-05-19
US20250100987A1 (en) 2025-03-27
EP4429656A4 (en) 2026-01-28

Similar Documents

Publication Publication Date Title
EP3442971B1 (en) Estrogen receptor modulators
EP3193855B1 (en) Bicyclic compounds
JP2021535909A (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト化合物
KR20170102885A (ko) 삼환성 스피로 화합물
JP2016518317A (ja) 二環式鎮痛化合物
JP2024543479A (ja) 多環式化合物
JP6847851B2 (ja) Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
US20220135579A1 (en) 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof
CN115038450A (zh) 组合
KR20190039125A (ko) 신규한 화합물 및 이의 용도
CN114149424A (zh) 用于治疗疾病的杂环化合物
JP6877359B2 (ja) イミダゾール誘導体
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
EP4499067A1 (en) Compounds for treating psychostimulant misuse
US7928134B2 (en) 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists
WO2024124050A1 (en) Multicyclic compounds
WO2024124043A1 (en) Multicyclic compounds
CN116133661A (zh) 淀粉样变性的治疗
JP2010539214A (ja) カンナビノイドｃｂ１受容体アゴニストとしての５−アリール−４，５−ジヒドロ−（１ｈ）−ピラゾール
HK40126954A (zh) 募集cereblon的bcl-xl/bcl-2双重降解剂
JP2023508324A (ja) 組み合わせ
AU2008263915A1 (en) 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
HK40004087B (en) Estrogen receptor modulators
HK40004087A (en) Estrogen receptor modulators
JP2020529403A (ja) アクリル酸類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110